What is the treatment for liver rejection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 10, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

From the Guidelines

Treatment for liver rejection involves a combination of immunosuppressive medications, with tacrolimus being the preferred calcineurin inhibitor due to its ability to reduce mortality and graft loss compared to cyclosporine 1. The standard approach begins with high-dose corticosteroids like methylprednisolone for acute rejection episodes. Maintenance immunosuppression usually includes a calcineurin inhibitor (tacrolimus), an antimetabolite (mycophenolate mofetil), and low-dose prednisone. Some key points to consider in the treatment of liver rejection include:

  • The use of tacrolimus trough levels should be kept at 6-10 ng/ml during the first month followed by 4-8 ng/ml thereafter 2
  • Combining tacrolimus with other immunosuppressive drugs (MMF, AZA or mTORi) to allow for a lower range of tacrolimus trough levels than recommended for monotherapy and to help preserve renal function 2
  • The administration of basiliximab induction with delayed introduction of tacrolimus is strongly recommended in patients at risk of developing post-transplant renal dysfunction 2
  • Exposure to CNIs should be minimised by employing combined immunosuppressive regimens, preferably an mTORi in the case of high risk of hepatic or extrahepatic cancer recurrence 2 For steroid-resistant rejection, stronger agents like antithymocyte globulin (ATG) or monoclonal antibodies such as basiliximab may be used. Some of the benefits of using these medications include:
  • Reduced incidence of acute rejection
  • Lower risk of graft loss
  • Improved patient survival
  • Minimized risk of renal dysfunction However, it is essential to carefully monitor drug levels to balance preventing rejection with avoiding toxicity and infection risks. Treatment adjustments are made based on the severity of rejection determined by liver biopsy findings, liver function tests, and the patient's overall condition. Early detection through regular blood tests is crucial for successful treatment, as chronic rejection is more difficult to reverse. Patients must adhere strictly to their medication regimen and follow up regularly with their transplant team to monitor for signs of rejection or medication side effects. In addition to medication, lifestyle modifications such as a healthy diet, regular exercise, and avoiding alcohol consumption can help prevent recurrent or de novo metabolic disorders after liver transplantation. Regular screening for alcohol biomarkers and addressing metabolic risk factors can also help prevent recurrent or de novo metabolic disorders. Adjustment of immunosuppression should be considered according to the kind of associated complication but should be balanced against the risk of rejection 2.

From the FDA Drug Label

Tacrolimus capsule is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver, kidney, or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants.

The treatment for liver rejection is tacrolimus in combination with other immunosuppressants, as it is indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver transplants 3.

  • The recommended initial oral dosage for liver transplant patients is 0.1 to 0.15 mg/kg/day capsules, divided in two doses, every 12 hours, with a whole blood trough concentration range of 5 to 20 ng/mL for the first year after transplant 3.
  • For pediatric liver transplant patients, the initial oral dosage is 0.15 to 0.2 mg/kg/day capsules, divided in two doses, every 12 hours, with a whole blood trough concentration range of 5 to 20 ng/mL for the first year after transplant 3.

From the Research

Treatment for Liver Rejection

The treatment for liver rejection typically involves the use of immunosuppressive medications to reduce the immune system's attack on the transplanted liver.

  • The most commonly used treatment is intravenous methylprednisolone, a high-dose steroid regimen 4.
  • The optimal dose and duration of the steroid regimen may vary, with some studies suggesting that a 6-day taper from 200 to 20 mg/d is more effective and safer than a 3-day course of 1,000 mg of methylprednisolone 4.
  • In cases where patients develop an allergic reaction to intravenous methylprednisolone, alternative treatments such as dexamethasone may be used 5.

Steroid-Resistant Acute Rejections

In some cases, liver transplant recipients may experience steroid-resistant acute rejections, which can be treated with antithymocyte globulin 6.

  • This treatment has been shown to be effective in 83.3% of patients with steroid-resistant acute rejection, with minimal adverse effects 6.
  • The use of antithymocyte globulin as a therapeutic option for steroid-resistant acute rejection is supported by studies, which highlight its acceptable adverse effects and effectiveness in treating this condition 6.

Acute and Chronic Rejection

Acute and chronic rejection are significant clinical concerns in liver transplant recipients, with acute rejection generally improving with steroid boluses and steroid-resistant rejection being uncommon 7.

  • Chronic rejection may improve with escalation of immunosuppression or may result in irreversible loss of graft function, leading to retransplantation or death 7.
  • The incidence of acute and chronic rejection has declined in recent years due to improved immunosuppressive regimens 7.

Incidence and Treatment of Acute Rejection

The incidence of acute rejection varies, with one study reporting that 33.5% of patients experienced acute rejection episodes 8.

  • High-doses of steroids have been shown to be effective in treating acute rejection, with no significant difference in liver function tests between patients treated with lower versus higher doses of methylprednisolone 8.
  • Recurrence of acute rejection is more common in patients treated with lower doses of methylprednisolone 8.

References

4
Research

Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002

5
Research

Methylprednisolone-Induced Hypersensitivity Reaction in a Liver Transplant Recipient.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2022

6
Research

Steroid-resistant acute rejections after liver transplant.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2010

7
Research

Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

Journal of clinical and experimental hepatology, 2017

Related Questions

Should I add NPH (neutral protamine Hagedorn) and continue the methylprednisolone IV infusion in a 44-year-old male, 3 days post‑liver transplant with decompensated cirrhosis, on prednisone 50 mg, receiving tube feeds (289 g carbohydrate/24 h) and impaired renal function (creatinine 2.67 mg/dL, GFR ≈ 29 mL/min)?
For a 67‑year‑old female liver transplant patient 11 days post‑operation on methylprednisolone 500 mg three times daily for acute rejection, weight 73 kg, creatinine 0.8 mg/dL (GFR ≈ 80 mL/min), with an insulin‑to‑carbohydrate ratio of 1 unit per 6 g carbohydrate and an insulin sensitivity factor of 25 mg/dL per unit, who received 15 units of neutral protamine Hagedorn (NPH) insulin with the 2 pm methylprednisolone dose, had a blood glucose of 254 mg/dL at 5 pm, started tube feeding at 8 pm providing 112 g carbohydrate over 12 hours, received 55 units of NPH at 8 pm, and had blood glucose readings of 380 mg/dL at 9 pm, 382 mg/dL at 1 am, 363 mg/dL at 8 am, and another methylprednisolone 500 mg dose at 8 am, what should the 8 am NPH dose be, what are the appropriate insulin sensitivity factor and insulin‑to‑carbohydrate ratio, and what should the evening (8 pm) NPH dose be?
Can solumedrol (methylprednisolone) be used to treat a full-body rash?
What is the management of moderate late acute cellular rejection (Rejection Activity Index score 5/9) following liver transplantation?
Is a single 125 mg intramuscular injection of Solu‑Medrol (methylprednisolone sodium succinate) appropriate for an adult with acute hives unresponsive to antihistamines?
What are the implications and treatment options for a urine pH of 8.5 (alkaluria) with pain in pregnancy?
Is amniotic fluid alkaline?
What is the recommended treatment for a urinary tract infection caused by Pseudomonas aeruginosa and Klebsiella pneumoniae with a urine culture showing greater than 100,000 CFU/mL of each organism?
How do you differentiate between hepatic and gallbladder issues using alkaline phosphatase (ALP) levels versus alanine transaminase (ALT) and aspartate transaminase (AST) levels?
What is the risk of malignancy associated with topical calcineurin inhibitors (TCIs), such as pimecrolimus (Elidel) and tacrolimus (Protopic), in patients with atopic dermatitis?
What is the recommended treatment for episodic genital herpes in immunocompromised patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.